‘Does the government have Rs 80,000 crore for the Kovid-19 vaccine?’: Adi Poonawalla of SII asked – India News

‘Does the government have Rs 80,000 crore for the Kovid-19 vaccine?’: Adi Poonawalla of SII asked – India News

Adar Poonawalla, CEO of Serum Institute of India, which conducts trials of quorumid-19 vaccine candidates, questioned the nation’s plan to produce and distribute shots against coronovirus disease on Saturday.

The Phase III trial of the vaccine candidate, developed by Oxford University and the British pharmaceutical company AstraZeneca, is underway as part of a production and testing deal with the Pune-based Serum Institute of India (SII) in India.

“Quick Question: Will the Government of India have Rs 80,000 crore available in the next one year? Because the Ministry of Health in India is required to purchase and distribute the vaccine. Poonawala tweeted, This is the next challenge we need to tackle.

“I ask this question, because we need to plan and guide vaccine manufacturers both in India and abroad in terms of procurement and distribution,” he said.

The Serum Institute, the world’s largest vaccine manufacturer by the number of doses produced, is working on a number of vaccine candidates against coronovirus disease – potentially being mass-produced, including AstraZeneca-Oxford University , Which has made headlines globally – as well as developing its own. .

US biotech firm CodeGenics Inc said on Tuesday that the Serum Institute of India has begun manufacturing its potential Kovid-19 vaccine and expects to begin human trials of the initial phase of the vaccine in the UK by the end of 2020. The Serum Institute will develop Codagnix’s CDX-005, which is distributed internally rather than injected.

Three more Kovid-19 vaccines in India are set to enter human trials, according to an official from the biotechnology department of the center supporting the development of several experimental coronavirus vaccines in the country.

The new vaccine candidates are from Genova Biopharmaceutical, Biolog e and Bharat Biotech, which have already developed one of two in clinical trials. The fifth Indian vaccine candidate to explain the preclinical stages is Zydus Cadila.

With 38 in human testing, more than 150 potential vaccines are being developed and tested globally, and candidates for Modern Inc., Pfizer Inc. and AstraZeneca PLC are already in final stage trials.


Leave a Reply

Your email address will not be published. Required fields are marked *